Aclaris Therapeutics (ACRS) SEC Filings: History & Chart

Aclaris Therapeutics, Inc.(ACRS)

Biotechnology · Wayne, PA

$3.93-0.34 (-8.08%)

Delayed quote: Oct 6, 2026, 12:40 PM EDT

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

Wayne, PA

71 employees

www.aclaristx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Neal S. Walker

View full financials

Form	Filing Date	Accepted	Document
SC 13G	Sep 21, 2026	Sep 21, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
S-3ASR	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
8-K	Jun 4, 2026	Jun 4, 2026	View filing
SC 13G/A	May 12, 2026	May 12, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
8-K	Apr 28, 2026	Apr 28, 2026	View filing
4	Apr 27, 2026	Apr 27, 2026	View filing
SC 13G/A	Apr 27, 2026	Apr 27, 2026	View filing
ARS	Apr 23, 2026	Apr 23, 2026	View filing
DEFA14A	Apr 23, 2026	Apr 23, 2026	View filing
DEF 14A	Apr 23, 2026	Apr 23, 2026	View filing
SC 13G	Apr 7, 2026	Apr 7, 2026	View filing
SC 13G/A	Mar 26, 2026	Mar 26, 2026	View filing
SC 13G	Mar 17, 2026	Mar 17, 2026	View filing
8-K	Mar 11, 2026	Mar 11, 2026	View filing
8-K	Mar 10, 2026	Mar 9, 2026	View filing
4	Mar 3, 2026	Mar 3, 2026	View filing

SEC Filings

Recent Filings